Kaleido Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
August 29, 2019 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 01, 2019 07:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the...
Kaleido Biosciences to Present at the 39th Annual Canaccord Genuity Growth Conference
July 31, 2019 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the...
Kaleido Biosciences Appoints Jerald Korn as General Counsel and Corporate Secretary
July 22, 2019 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the...
Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors
July 15, 2019 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the...
Kaleido Biosciences to Highlight Chemistry-Driven Approach at Microbiome Movement – Drug Development Summit
June 26, 2019 08:00 ET
|
Kaleido Biosciences
Members of leadership team to participate in sessions discussing the role of the microbiome in human disease Summit coincides with World Microbiome Day: June 27, 2019 LEXINGTON, Mass., June 26,...
Kaleido Biosciences to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
June 03, 2019 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
Kaleido Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 02, 2019 07:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
Kaleido Biosciences Announces Presentation of Clinical Study and Ex Vivo Data Supporting the Development of Novel Microbiome Metabolic Therapies for Hyperammonemia at The International Liver Congress™ 2019 (EASL)
April 12, 2019 07:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., April 12, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
Kaleido Biosciences Announces Key Appointments to Leadership Team
April 08, 2019 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...